Lipocine To Announce Phase 3 Data For LPCN 1154 Treatment For Postpartum Depression On May 26
Benzinga Newsdesk 5 months ago
News
Oral Presentation detailsTitle:Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpartum Depression: A Placebo-Controlled Phase 3 Clinical Trial of LPCN 1154Presenter:Benjamin Bruno, PhD, Vice
| Oral Presentation details | |
| Title: | Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpartum Depression: A Placebo-Controlled Phase 3 Clinical Trial of LPCN 1154 |
| Presenter: | Benjamin Bruno, PhD, Vice President, Clinical Development, Lipocine |
| Session: | Pharmaceutical Pipeline (Oral Presentation) |
| Date: | Tuesday, May 26, 2026 |
| Time: | 3:20 PM ET |
| Location: | Loews Miami Beach Hotel, Miami, FL |
The presentation will highlight results from Lipocine's Phase 3 placebo-controlled trial evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD).
| Poster Presentation | |
| Date: | Wednesday, May 27, 2026 |
| Time: | 11:45 AM – 1:30 PM ET |
| Session: | Poster Session 1, Pharmaceutical Pipeline |
| Poster number: | W98 |